(Reuters) - Private equity firm Carlyle Group is in exclusive talks to acquire Baxter International's kidney care spinoff Vantive for more than $4 billion, including debt, a person familiar with the matter told Reuters on Friday. Shares of the Deerfield, Illinois-based firm rose about 4%. The parties had entered exclusive negotiations in late June, the person said, adding that a deal could be announced in the coming weeks. Medical device maker Baxter said in March it had been in discussions with select private equity investors to explore a potential sale of the kidney care unit more than a year after it announced plans to separate the unit amid supply-chain challenges and weak demand for dialysis operations. Baxter had said it plans to separate the unit in the second half of the year. Carlyle and Baxter did not immediately respond to Reuters' requests for comment. The Wall Street Journal first reported on the matter. (Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar and Krishna Chandra Eluri)
Carlyle in talks to buy Baxter's kidney care unit, source says
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...